{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:43:12Z","timestamp":1792748592377,"version":"4.5.0"},"reference-count":42,"publisher":"American Chemical Society (ACS)","issue":"20","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"name":"State Commission of Science & Technology of China","award":["2016YFC0104100"],"award-info":[{"award-number":["2016YFC0104100"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82127806"],"award-info":[{"award-number":["82127806"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82502430"],"award-info":[{"award-number":["82502430"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Tumor heterogeneity limits the diagnostic performance of molecular imaging probes targeting a single biomarker. Here, we report the design, synthesis, and preclinical evaluation of 68Ga-labelled heterodimeric radiotracers co-targeting integrin \u03b1v\u03b23 and poly(ADP-ribose) polymerase 1 (PARP1) through a proposed \u201cbinding\u2212anchoring\u201d concept strategy. Conjugating the tumor-penetrating iRGD peptide with the PARP1 inhibitor niraparib and incorporating an albumin-binding moiety yielded the lead probe [68Ga] Ga-NY-Dual-IP. Molecular docking and surface plasmon resonance supported nanomolar target-binding capability of the corresponding non-radiolabeled precursors. In the 4T1 breast cancer model, [68Ga] Ga-NY-Dual-IP exhibited a tumor uptake of 7.29 \u00b1 0.28% ID\/g at 1 h, approximately 4\u22125-fold higher than that of the corresponding single-target probes. Cytotoxicity, haemolysis and histopathological analyses confirmed excellent biocompatibility. These findings established [68Ga] Ga-NY-Dual-IP as a promising PET probe for precise tumor imaging and potential clinical translation.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c01653","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:33:38Z","timestamp":1791297218000},"page":"24121-24136","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical Evaluation of 68Ga-Labeled Heterodimers for Dual Integrin \u03b1v\u03b23 and PARP1-Targeted Tumor Imaging"],"prefix":"10.1021","volume":"69","author":[{"given":"Congjie","family":"He","sequence":"first","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Li","sequence":"additional","affiliation":[{"name":"Nanjing University , , ,","place":["Nanjing, China, 210023"]},{"name":"Nanjing Nuoyuan Medical Devices Co. Ltd. , ,","place":["Nanjing, China, 210006"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0490-1677","authenticated-orcid":true,"given":"Pengfei","family":"Dai","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , ,","place":["Hefei, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew James","family":"Chandra","sequence":"additional","affiliation":[{"name":"Nanjing University , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junming","family":"Dong","sequence":"additional","affiliation":[{"name":"Nanjing University , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiming","family":"Cai","sequence":"additional","affiliation":[{"name":"Nanjing Nuoyuan Medical Devices Co. Ltd. , ,","place":["Nanjing, China, 210006"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Si","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Anhui Medical University , , ,","place":["Hefei, China, 230022"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"He","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5626-8589","authenticated-orcid":true,"given":"Yiqing","family":"Wang","sequence":"additional","affiliation":[{"name":"Nanjing University , , ,","place":["Nanjing, China, 210023"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"2026102305072638200_cit1","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2967\/jnumed.116.188045","article-title":"Molecular imaging in cancer drug development","volume":"59","author":"Waaijer","year":"2018","journal-title":"J. Nucl. Med."},{"key":"2026102305072638200_cit2","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/nature12627","article-title":"Tumour heterogeneity in the clinic","volume":"501","author":"Bedard","year":"2013","journal-title":"Nature"},{"key":"2026102305072638200_cit3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-025-02360-2","article-title":"Cancer stem cells: landscape, challenges and emerging therapeutic innovations","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduction Targeted Ther."},{"key":"2026102305072638200_cit4","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00259-024-06634-9","article-title":"Synthesis, preclinical, and initial clinical evaluation of integrin \u03b1V\u03b23 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03","volume":"51","author":"Wen","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit5","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00726-010-0546-y","article-title":"Peptide heterodimers for molecular imaging","volume":"41","author":"Yan","year":"2011","journal-title":"Amino Acids"},{"key":"2026102305072638200_cit6","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00259-023-06587-5","article-title":"A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET\/CT imaging","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit7","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1007\/s00259-020-04975-9","article-title":"Non-oncological applications of RGD-based single-photon emission tomography and positron emission tomography agents","volume":"48","author":"Ebenhan","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit8","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s00259-023-06249-6","article-title":"PET imaging of PARP expression using 68Ga-labelled inhibitors","volume":"50","author":"Wang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction Targeted Ther."},{"key":"2026102305072638200_cit10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc2748","article-title":"Integrins in cancer: biological implications and therapeutic opportunities","volume":"10","author":"Desgrosellier","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"2026102305072638200_cit11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.62347\/gtzz9726","article-title":"Evaluation of 18F-FAPI-42-RGD as a novel dual-targeting PET tracer in gastric cancer xenograft models","volume":"15","author":"Zhao","year":"2025","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit12","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit13","doi-asserted-by":"publisher","first-page":"12803","DOI":"10.1021\/acs.analchem.5c01857","article-title":"Development of 68Ga-NOTA-cRGD Probe Mediated by Sulfenic Acid for Prolonging Tumor Imaging","volume":"97","author":"Xue","year":"2025","journal-title":"Anal. Chem."},{"key":"2026102305072638200_cit14","doi-asserted-by":"publisher","first-page":"21343","DOI":"10.1021\/acsami.9b03542","article-title":"Positron Emission Tomography\/Magnetic Resonance Imaging of Glioblastoma Using a Functionalized GadofullereneNanoparticle","volume":"11","author":"Chen","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2026102305072638200_cit15","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.21037\/tlcr-24-589","article-title":"Enhanced tumor targeting and penetration of fluorophores via iRGD peptide conjugation: a strategy for the precision targeting of lung cancer","volume":"13","author":"Li","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"key":"2026102305072638200_cit16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13550-021-00776-9","article-title":"Angiogenesis imaging study using interim [18F] RGD-K5 PET\/CT in patients with lymphoma undergoing chemotherapy: preliminary evidence","volume":"11","author":"Tonnelet","year":"2021","journal-title":"EJNMMI Res."},{"key":"2026102305072638200_cit17","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.7150\/thno.22601","article-title":"68Ga-BBN-RGD PET\/CT for GRPR and Integrin \u03b1v\u03b23 Imaging in Patients with Breast Cancer","volume":"8","author":"Zhang","year":"2018","journal-title":"Theranostics"},{"key":"2026102305072638200_cit18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2967\/jnumed.116.177048","article-title":"Clinical Translation of a Dual Integrin \u03b1v\u03b23 and Gastrin-Releasing Peptide Receptor\u2212Targeting PET Radiotracer, 68Ga-BBN-RGD","volume":"58","author":"Zhang","year":"2017","journal-title":"J. Nucl. Med."},{"key":"2026102305072638200_cit19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/bjc.2012.581","article-title":"Cancer heterogeneity: implications for targeted therapeutics","volume":"108","author":"Fisher","year":"2013","journal-title":"Br. J. Cancer"},{"key":"2026102305072638200_cit20","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"2026102305072638200_cit21","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.7150\/thno.79144","article-title":"Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [68Ga]Ga-FAPI-RGD","volume":"12","author":"Zang","year":"2022","journal-title":"Theranostics"},{"key":"2026102305072638200_cit22","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1021\/mp060049x","article-title":"Radiolabeled multimeric cyclic RGD peptides as integrin \u03b1V\u03b23 targeted radiotracers for tumor imaging","volume":"3","author":"Liu","year":"2006","journal-title":"Mol. Pharmaceutics"},{"key":"2026102305072638200_cit23","doi-asserted-by":"publisher","first-page":"7036","DOI":"10.1021\/acs.molpharmaceut.5c01089","article-title":"Lipophilicity-Optimized PARP-1 Tracers: Minimizing Hepatic Retention for Enhanced Target-to-Background PET Imaging","volume":"22","author":"Xie","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026102305072638200_cit24","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1021\/acs.molpharmaceut.4c01237","article-title":"Development of 99mTc-Labeled Complexes with aNiraparib HYNIC Derivative for PARP-Positive Tumor Imaging","volume":"22","author":"Wang","year":"2025","journal-title":"Mol. Pharmaceutics"},{"key":"2026102305072638200_cit25","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","article-title":"The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets","volume":"39","author":"Krishnakumar","year":"2010","journal-title":"Mol. Cell"},{"key":"2026102305072638200_cit26","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s00259-023-06249-6","article-title":"PET imaging of PARP expression using 68Ga-labelled inhibitors","volume":"50","author":"Wang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit27","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1200\/edbk_158808","article-title":"Tumor Heterogeneity and Therapeutic Resistance","volume":"36","author":"Lovly","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"2026102305072638200_cit28","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.phrs.2023.106694","article-title":"The Challenges and Opportunities of \u03b1v\u03b23-Based Therapeutics in Cancer: From Bench to Clinical Trials","volume":"189","author":"Gu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"10","key":"2026102305072638200_cit29","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","article-title":"The Multifaceted Roles of PARP1 in DNA Repair and Chromatin Remodelling","volume":"18","author":"Ray Chaudhuri","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"2026102305072638200_cit30","doi-asserted-by":"publisher","first-page":"9367845","DOI":"10.1155\/2019\/9367845","article-title":"iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers","volume":"2019","author":"Zuo","year":"2019","journal-title":"J. Oncol."},{"key":"2026102305072638200_cit31","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1126\/science.1183057","article-title":"Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs","volume":"328","author":"Sugahara","year":"2010","journal-title":"Science"},{"key":"2026102305072638200_cit32","doi-asserted-by":"publisher","first-page":"16157","DOI":"10.1073\/pnas.0908201106","article-title":"C-end rule peptides mediate neuropilin-1-dependent cell, vascular, and tissue penetration","volume":"106","author":"Teesalu","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"2026102305072638200_cit33","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00259-024-06623-y","article-title":"Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin \u03b1V\u03b23","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00259-023-06587-5","article-title":"A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET\/CT imaging","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit35","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.2967\/jnumed.122.265383","article-title":"Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin \u03b1v\u03b23 in Various Cancer Types","volume":"64","author":"Zhao","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026102305072638200_cit36","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1007\/s00259-024-06623-y","article-title":"Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin \u03b1V\u03b23","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit37","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1007\/s00259-024-06634-9","article-title":"Synthesis, preclinical, and initial clinical evaluation of integrin \u03b1V\u03b23 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03","volume":"51","author":"Wen","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit38","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1007\/s00259-024-06965-7","article-title":"Design, preclinical evaluation, and first-in-human PET study of [68Ga]Ga-PSFA-01: a PSMA\/FAP heterobivalent tracer","volume":"52","author":"Wang","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit39","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/ird3.62","article-title":"Elevating theranostics: The emergence and promise of radiopharmaceutical cell-targeting heterodimers in human cancers","volume":"2","author":"Chambers","year":"2024","journal-title":"iRadiology"},{"key":"2026102305072638200_cit40","doi-asserted-by":"publisher","first-page":"5628","DOI":"10.3390\/jcm14165628","article-title":"Bispecific Radioligands (BRLs): Two Is Better Than One","volume":"14","author":"Bentivoglio","year":"2025","journal-title":"J. Clin. Med."},{"key":"2026102305072638200_cit41","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1007\/s00259-009-1123-z","article-title":"68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging","volume":"36","author":"Liu","year":"2009","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"2026102305072638200_cit42","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.apsb.2021.09.032","article-title":"Preclinical evaluation and pilot clinical study of [18F]AlF-labeled FAPI-tracer for PET imaging of cancer associated fibroblasts","volume":"12","author":"Hu","year":"2022","journal-title":"Acta Pharm. Sin. B"}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c01653","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24121\/68755300\/jm6c01653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/20\/24121\/68755300\/jm6c01653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T09:17:51Z","timestamp":1792747071000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/20\/24121\/5445144\/Preclinical-Evaluation-of-68Ga-Labeled"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":42,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2026,10,6]]},"published-print":{"date-parts":[[2026,10,22]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c01653","relation":{},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]}}}